Trump Administration’s Partial Cannabis Rescheduling: What It Means
Background on the Executive Order
In late April 2026, Acting Attorney General Todd Blanche signed an order that moves certain cannabis‑related products from Schedule I to Schedule III of the Controlled Substances Act. Schedule I is reserved for substances deemed to have no accepted medical use and a high potential for abuse, whereas Schedule III includes drugs with accepted medical uses that are still regulated, such as low‑dose Tylenol with codeine and ketamine.
The order specifically removes two categories from Schedule I:
- Products sold under state‑issued medical cannabis licenses.
- Any future cannabis‑based product that receives FDA approval.
According to Blanche’s statement, the change aligns U.S. policy with the Single Convention on Narcotic Drugs (1961), a United Nations treaty to which 73 nations, including the United States, are parties. The convention requires that narcotics such as cannabis be produced only in limited quantities and strictly for scientific and medical purposes.
Expert Reaction: A Move Toward Clarity, But Many Questions Remain
Cat Packer, director of drug markets and legal regulation at the Drug Policy Alliance, welcomed the shift while noting its limits. “While some marijuana‑related products are no longer being treated as schedule I, it’s not accurate to say marijuana has been broadly rescheduled – this is partial rescheduling, at best,” Packer said.
She highlighted two concerns that industry observers have raised:
- The FDA‑approved clause applies only to prospective products; it does not affect the handful of cannabis‑derived medicines already approved by the FDA, such as Epidiolex (cannabidiol for seizures), Marinol and Syndros (synthetic THC for nausea), and Cesamet (nabilone for chemotherapy‑induced vomiting).
- By pre‑emptively scheduling any future FDA‑approved cannabis drug, the order may bypass the usual evidence‑based risk evaluation that the DEA conducts before changing a substance’s schedule.
Industry Voices: Confusion and Caution
Ryan Hunter, chief revenue officer at Colorado‑based Spherex Labs, called the announcement “a very silly announcement” and questioned who thought it would be helpful. Hunter pointed out that his company holds a dual license allowing both medical and adult‑use sales, yet the products themselves are identical.
“They’re exactly the same products. The cost is the same, the facilities are the same, the employees are the same.” – Ryan Hunter, Spherex Labs
Alex Gonzalez, co‑founder and president of Calyx Containers, speculated that the timing of the move was politically motivated, noting upcoming midterm elections and a desire to appease younger male voters. Gonzalez also referenced the recent departure of former Attorney General Pam Bondi, whom he described as a long‑time blocker of cannabis reform.
Impact on Medical Cannabis Patients and Providers
For patients who rely on medical cannabis, the reclassification carries symbolic weight. Packer explained that “these products are now federally recognized as legitimate medicine, signaling a meaningful shift in federal policy; patients and their caregivers should no longer be treated as criminals under federal law.”
However, the order leaves many practical questions unresolved. Because the DEA has not yet issued guidance on how providers should register or how state‑level programs will interact with the new federal status, patients could still face discrimination in housing, employment, or access to banking services.
Equity Considerations: Who Benefits Most?
Packer warned that the narrow focus on medical cannabis may exacerbate existing inequities. “In practice, this disproportionately excludes Black and Latino cannabis entrepreneurs, who are more likely to hold adult‑use licenses due to the high barriers to entry in early medical markets,” she said. Equity programs that have helped diversify the industry have largely grown out of adult‑use legalization, not medical‑only frameworks.
Thus, while the order may protect patients and medical providers, it could leave many entrepreneurs who built businesses around recreational sales without the same federal protections.
Looking Ahead: The DEA Hearings and the Path to Full Rescheduling
Blanche also announced that the DEA will hold an administrative hearing on rescheduling on 29 June 2026. Packer cautioned that full rescheduling remains “far from guaranteed,” and even if marijuana is moved to a less restrictive schedule, it would still fall short of the will of the majority of Americans. Polling by the Pew Research Center in 2023 showed that approximately 68 % of U.S. adults support full legalization of cannabis.
Until clearer federal guidance emerges, industry stakeholders advise caution, thorough documentation, and continued engagement with both state regulators and federal agencies to navigate the evolving landscape.
For the original reporting, see the source: Here
